TransMedics Group, Inc. (TMDX) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Medical - Devices industria. La empresa tiene su sede en Andover, MA, United States. El CEO actual es Waleed H. Hassanein.
TMDX tiene fecha de IPO 2019-05-02, 728 empleados a tiempo completo, cotiza en el NASDAQ Global Market, una capitalización de mercado de $3.97B.
TransMedics Group, Inc. is a commercial-stage medical technology company headquartered in Andover, Massachusetts, focused on transforming organ transplant therapy for end-stage organ failure patients globally. The company develops and commercializes the Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring platform that uses proprietary technology to maintain near-physiologic conditions for donor organs outside the human body. Its product portfolio includes OCS LUNG for lung preservation, OCS Heart for cardiac preservation, and OCS Liver for hepatic preservation, each designed to improve transplant outcomes and expand the pool of viable organs. Founded in 1998, TransMedics addresses critical challenges in organ transplantation through innovative ex vivo organ preservation technology.
